X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Mid & small caps bleed 
(Fri, 12 Dec Closing) 
 
After trading in the negative territory during post noon trading session, the Indian equity markets lost further ground and closed in the red. While the BSE-Sensex today closed lower by 251 points, the NSE-Nifty closed lower by 69 points. Midcaps and Smallcaps too closed in the red today. While the BSE Mid Cap index was down by 1.28%, the BSE Small Cap index closed lower by 1.5%. oil and gas and realty stocks were the biggest losers today.

As regards global markets, Asian pack closed strong today. The rupee was trading at Rs 62.34 odd levels to the dollar at the time of writing.

The management of TTK Prestige revised it sales guidance downwards to 12-14% from 25% for FY15. The primary reason has been muted sales during the Diwali season. The company expected strong sales growth during the festive season but it stood at just 10% compared to the last year. Another factor which is expected to impact the sales growth is the power situation in Southern markets. Since the company is into induction cook tops, uninterrupted power supply is key factor for the sale of its products. While the power situation has improved a bit the deficit in Tamil Nadu has worsened. This has also hurt the company a bit. As far as EBITDA margins are concerned, they are expected to remain in the range of 12%.

Healthcare stocks have ended the day on a mixed note. The Indian pharma pricing authority has capped the prices of 52 more drugs which include painkillers, cancer and skin care medicines as well as antibiotics. It may be noted that currently 400 odd drugs are under the pricing control. The companies that typically manufacture these 52 drugs include Lupin, Cadila Healthcare and Merck. Hence, these companies will be the most impacted by the new ruling as they will not be able to charge higher prices.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Mid & small caps bleed". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS